InvestSMART

Radiopharm Theranostics Limited (ASX: RAD) - Announcements

- Current share price for RAD : $0.012

ASX company news and announcements for Radiopharm Theranostics Limited (RAD) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Radiopharm Theranostics Limited (RAD) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Radiopharm Theranostics Limited (RAD), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Radiopharm Theranostics Limited (RAD)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$52 New Class Options Range of Units and Top 20 Holders 9 Dec 2025 10:17AM $0.020 $0.012 fallen by 38.46%
$52 Application for quotation of securities - RAD 5 Dec 2025 9:56AM $0.021 $0.012 fallen by 42.86%
$52 Results of Meeting 3 Dec 2025 6:18PM $0.022 $0.012 fallen by 45.45%
$52 Share purchase plan completed 3 Dec 2025 4:40PM $0.022 $0.012 fallen by 45.45%
$52 Ceasing to be a substantial holder 1 Dec 2025 8:15AM $0.022 $0.012 fallen by 45.45%
$52 Notification of cessation of securities - RAD 25 Nov 2025 5:22PM $0.021 $0.012 fallen by 42.86%
$52 Final Director's Interest Notice - PH 25 Nov 2025 4:54PM $0.021 $0.012 fallen by 42.86%
$52 Final Director's Interest Notice - LA 25 Nov 2025 4:51PM $0.021 $0.012 fallen by 42.86%
$52 Results of Meeting 20 Nov 2025 1:05PM $0.022 $0.012 fallen by 45.45%
$52 Presentation to Annual General Meeting 20 Nov 2025 8:57AM $0.022 $0.012 fallen by 45.45%
$52 Initial Director's Interest Notice 19 Nov 2025 12:43PM $0.022 $0.012 fallen by 45.45%
$52 Life Sciences Leader Bruce Goodwin Appointed to Board 19 Nov 2025 12:43PM $0.022 $0.012 fallen by 45.45%
$52 RAD Approval for Phase 1 Therapeutic Trial of RAD 402 18 Nov 2025 8:31AM $0.023 $0.012 fallen by 47.83%
$52 RAD Announces 50% Enrollment in Phase 2b Trial of RAD101 17 Nov 2025 8:28AM $0.022 $0.012 fallen by 45.45%
$52 RAD starts enrollment of 3rd Cohort of Phase 1 177Lu-RAD204 12 Nov 2025 10:35AM $0.024 $0.012 fallen by 50%
$52 Disclosure of Long Equity Derivative Positions 6 Nov 2025 11:18AM $0.023 $0.012 fallen by 47.83%
$52 Notice of Extraordinary General Meeting and Proxy Form 4 Nov 2025 9:17AM $0.025 $0.012 fallen by 52%
$52 Presenting at Deutsche Bank ADR Virtual Investor Conference 3 Nov 2025 12:17PM $0.025 $0.012 fallen by 52%
$52 Change of Director's Interest Notice (RC) 3 Nov 2025 10:53AM $0.025 $0.012 fallen by 52%
$52 Change in substantial holding 28 Oct 2025 7:46PM $0.023 $0.012 fallen by 47.83%
$52 Change in substantial holding PH 28 Oct 2025 4:48PM $0.023 $0.012 fallen by 47.83%
$52 Change in substantial holding 28 Oct 2025 4:43PM $0.023 $0.012 fallen by 47.83%
$52 Quarterly Activities/Appendix 4C Cash Flow Report 28 Oct 2025 2:32PM $0.023 $0.012 fallen by 47.83%
$52 Notice Under Section 708A 24 Oct 2025 2:52PM $0.026 $0.012 fallen by 52.94%
$52 Application for quotation of securities - RAD 24 Oct 2025 2:48PM $0.025 $0.012 fallen by 52%

51 - 75 of 609 results

Page 3 of 25

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.